WNK-IN-11-d 3 is an orally active, selective and potent With-No-Lysine (WNK) kinase inhibitor. WNK-IN-11-d 3 is effective at regulating cardiovascular homeostasis. In Vivo WNK-IN-11 D3 (1.5 mg/kg; p.o.) shows an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability . WNK-IN-11 D3 (30 mg/kg; p.o.) shows significant reductions in systolic blood pressure (SBP) vs untreated mice . WNK-IN-11 D3 (0~100 mg/kg; p.o.) induces dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg . WNK-IN-11 D3 shows trends toward reduction of blood pressure, stroke volume, and total peripheral resistance, while increasing heart rate. WNK-IN-11 D3 shows efficacy in rodent models of hypertension and volume overload . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Sprague−Dawley rats Dosage: 1.5 mg/kg Administration: P.o. Result: Showed an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability. Animal Model: FVB mice Dosage: 30 mg/kg Administration: P.o. Result: Showed significant reductions in systolic blood pressure (SBP) vs untreated mice. Animal Model: FVB mice Dosage: 0~100 mg/kg Administration: P.o. Result: Induced dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg. Form:Solid IC50& Target:WNK